BEAM

SEC source: 0000950170-23-027046 · ownership.xml · derivative · entry 1

Walsh Kathleen E · CIK 0001667866 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 16,532

Underlying: Common Stock · 16,532 shares

Expires 2023-06-06

F1 · derivative.exercise_date: The option vests in full on the earlier of the first anniversary of the date of grant and the date of the next year's annual meeting of stockholders, subject to the reporting person's continued service to the board of directors of Beam Therapeutics Inc. through the vesting date.

SEC source: 0001193125-26-412236 · ownership.xml · nonDerivative · entry 1

Cavanagh Bethany J · CIK 0002033155 · SVP, Finance and Treasurer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 50,984

F1 · kind: These shares of common stock were automatically sold in a non-discretionary transaction by the Reporting Person in order to cover tax withholding obligations upon the vesting of certain restricted stock units granted to the Reporting Person under the Beam Therapeutics Inc. 2019 Equity Incentive Plan on September 30, 2024. The sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 9, 2024.

SEC source: 0001193125-26-402814 · ownership.xml · nonDerivative · entry 1

Ciaramella Giuseppe · CIK 0001786322 · President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 130,504

F1 · balance_after: On September 24, 2026, the reporting person contributed 123,407 shares of BEAM common stock to the Giuseppe Ciaramella Irrevocable Trust - 2026, of which the reporting person's spouse is trustee. The beneficiaries of the trust are the reporting person's spouse and children. The reporting person disclaims beneficial ownership of the securities held by the trust.

SEC source: 0001193125-26-323640 · ownership.xml · nonDerivative · entry 1

Simon Amy · CIK 0001963879 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 85,696

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 27, 2026.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $25.32 to $26.05, inclusive. The Reporting Person undertakes to provide to Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

SEC source: 0001193125-26-292526 · ownership.xml · derivative · entry 11

Evans John M. · CIK 0001786304 · Director · CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 205,804

Underlying: Common Stock · 25,000 shares

Expires 2028-07-13

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The stock options were exercised and the shares of common stock were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 16, 2025.

F7 · derivative.exercise_date: On July 13, 2018, the Reporting Person was granted an option to purchase 539,645 shares of common stock, which vested as to 25% of the underlying shares on January 8, 2019 and in 36 equal monthly installments thereafter.

SEC source: 0001193125-26-292526 · ownership.xml · nonDerivative · entry 7

Evans John M. · CIK 0001786304 · Director · CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,047,205

F1 · kind: The stock options were exercised and the shares of common stock were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 16, 2025.

F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $34.83 to $34.85, inclusive. The Reporting Person undertakes to provide to BEAM, any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

SEC source: 0001193125-26-292526 · ownership.xml · nonDerivative · entry 6

Evans John M. · CIK 0001786304 · Director · CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,049,105

F1 · kind: The stock options were exercised and the shares of common stock were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 16, 2025.

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $33.80 to $34.71, inclusive. The Reporting Person undertakes to provide to BEAM, any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

SEC source: 0001193125-26-292526 · ownership.xml · nonDerivative · entry 5

Evans John M. · CIK 0001786304 · Director · CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,072,205

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The stock options were exercised and the shares of common stock were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 16, 2025.

SEC source: 0001193125-26-294478 · ownership.xml · nonDerivative · entry 1

Simon Amy · CIK 0001963879 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 102,363

F1 · kind: These shares of common stock were automatically sold in a non-discretionary transaction by the Reporting Person in order to cover tax withholding obligations upon the vesting of certain restricted stock units granted to the Reporting Person under the Beam Therapeutics Inc. ("BEAM") 2019 Equity Incentive Plan on June 30, 2022. The sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 19, 2023.

SEC source: 0001193125-26-292526 · ownership.xml · derivative · entry 10

Evans John M. · CIK 0001786304 · Director · CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 230,804

Underlying: Common Stock · 6,337 shares

Expires 2028-07-13

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The stock options were exercised and the shares of common stock were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 16, 2025.

F7 · derivative.exercise_date: On July 13, 2018, the Reporting Person was granted an option to purchase 539,645 shares of common stock, which vested as to 25% of the underlying shares on January 8, 2019 and in 36 equal monthly installments thereafter.

SEC source: 0001193125-26-292526 · ownership.xml · derivative · entry 9

Evans John M. · CIK 0001786304 · Director · CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 9

Underlying: Common Stock · 18,663 shares

Expires 2028-05-08

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The stock options were exercised and the shares of common stock were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 16, 2025.

F6 · derivative.exercise_date: On May 8, 2018, the Reporting Person was granted an option to purchase shares of common stock, which vested as to 99,396 shares upon the achievement of a certain development milestone related to base editing applications. On April 3, 2024, the board of directors of BEAM determined that this performance condition was achieved, resulting in the vesting of 99,336 shares.

SEC source: 0001193125-26-292526 · ownership.xml · nonDerivative · entry 4

Evans John M. · CIK 0001786304 · Director · CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,047,205

F1 · kind: The stock options were exercised and the shares of common stock were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 16, 2025.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $35.60 to $36.18, inclusive. The Reporting Person undertakes to provide to BEAM, any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

SEC source: 0001193125-26-292526 · ownership.xml · nonDerivative · entry 3

Evans John M. · CIK 0001786304 · Director · CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,058,784

F1 · kind: The stock options were exercised and the shares of common stock were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 16, 2025.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $34.55 to $35.50, inclusive. The Reporting Person undertakes to provide to Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

SEC source: 0001193125-26-292526 · ownership.xml · nonDerivative · entry 2

Evans John M. · CIK 0001786304 · Director · CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,072,205

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The stock options were exercised and the shares of common stock were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 16, 2025.

SEC source: 0001193125-26-292526 · ownership.xml · nonDerivative · entry 1

Evans John M. · CIK 0001786304 · Director · CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,065,868

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The stock options were exercised and the shares of common stock were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 16, 2025.

SEC source: 0001193125-26-288078 · ownership.xml · nonDerivative · entry 2

FMR LLC · CIK 0000315066 · 10% owner · See Remark 1

10b5-1 filing: No plan indicated

Ownership: Indirect · F-Prime Capital Partners Healthcare Fund V LP

Disclosed balance after: 854,583

F2 · price: The price reported for this transaction is the weighted average price of multiple trades at prices ranging from $35.00 to $35.88. FMR LLC hereby undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer full information.

SEC source: 0001193125-26-288078 · ownership.xml · nonDerivative · entry 1

FMR LLC · CIK 0000315066 · 10% owner · See Remark 1

10b5-1 filing: No plan indicated

Ownership: Indirect · F-Prime Capital Partners Healthcare Fund V LP

Disclosed balance after: 1,106,071

F1 · price: The price reported for this transaction is the weighted average price of multiple trades at prices ranging from $35.00 to $35.39. FMR LLC hereby undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer full information.

SEC source: 0001193125-26-277509 · ownership.xml · derivative · entry 4

Ciaramella Giuseppe · CIK 0001786322 · President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 56,946

Underlying: Common Stock · 29,000 shares

Expires 2028-07-13

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: The shares subject to these stock options vested 25% on the first anniversary of the vesting commencement dates, February 26, 2018, and the remaining shares vested in 36 substantially equal monthly installments thereafter.

SEC source: 0001193125-26-277509 · ownership.xml · derivative · entry 3

Ciaramella Giuseppe · CIK 0001786322 · President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 6,505 shares

Expires 2028-05-08

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: The shares subject to these stock options vested 25% on the first anniversary of the vesting commencement dates, February 26, 2018, and the remaining shares vested in 36 substantially equal monthly installments thereafter.

SEC source: 0001193125-26-277509 · ownership.xml · nonDerivative · entry 2

Ciaramella Giuseppe · CIK 0001786322 · President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 253,911

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001193125-26-277509 · ownership.xml · nonDerivative · entry 1

Ciaramella Giuseppe · CIK 0001786322 · President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 224,911

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001193125-26-259524 · ownership.xml · derivative · entry 1

MARAGANORE JOHN · CIK 0001180432 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 19,676

Underlying: Common Stock · 19,676 shares

Expires 2036-06-03

F1 · derivative.exercise_date: The option vests in full on the earlier of the first anniversary of the date of grant and immediately prior to the date of the next year's annual meeting of stockholders, subject to the reporting person's continued service to the board of directors of Beam Therapeutics Inc. through the vesting date.

SEC source: 0001193125-26-259529 · ownership.xml · derivative · entry 1

Shaw Christi · CIK 0001702473 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 19,676

Underlying: Common Stock · 19,676 shares

Expires 2036-06-03

F1 · derivative.exercise_date: The option vests in full on the earlier of the first anniversary of the date of grant and immediately prior to the date of the next year's annual meeting of stockholders, subject to the reporting person's continued service to the board of directors of Beam Therapeutics Inc. through the vesting date.

SEC source: 0001193125-26-259526 · ownership.xml · derivative · entry 1

Walsh Kathleen E · CIK 0001667866 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 19,676

Underlying: Common Stock · 19,676 shares

Expires 2036-06-03

F1 · derivative.exercise_date: The option vests in full on the earlier of the first anniversary of the date of grant and immediately prior to the date of the next year's annual meeting of stockholders, subject to the reporting person's continued service to the board of directors of Beam Therapeutics Inc. through the vesting date.

SEC source: 0001193125-26-259536 · ownership.xml · derivative · entry 1

Fishman Mark · CIK 0001786003 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 19,676

Underlying: Common Stock · 19,676 shares

Expires 2036-06-03

F1 · derivative.exercise_date: The option vests in full on the earlier of the first anniversary of the date of grant and immediately prior to the date of the next year's annual meeting of stockholders, subject to the reporting person's continued service to the board of directors of Beam Therapeutics Inc. through the vesting date.

SEC source: 0001193125-26-259534 · ownership.xml · derivative · entry 1

Guindo Chirfi · CIK 0001722753 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 19,676

Underlying: Common Stock · 19,676 shares

Expires 2036-06-03

F1 · derivative.exercise_date: The option vests in full on the earlier of the first anniversary of the date of grant and immediately prior to the date of the next year's annual meeting of stockholders, subject to the reporting person's continued service to the board of directors of Beam Therapeutics Inc. through the vesting date.

SEC source: 0001193125-26-259519 · ownership.xml · derivative · entry 1

COOPER GRAHAM K · CIK 0001396943 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 19,676

Underlying: Common Stock · 19,676 shares

Expires 2036-06-03

F1 · derivative.exercise_date: The option vests in full on the earlier of the first anniversary of the date of grant and immediately prior to the date of the next year's annual meeting of stockholders, subject to the reporting person's continued service to the board of directors of Beam Therapeutics Inc. through the vesting date.

SEC source: 0001193125-26-144068 · ownership.xml · nonDerivative · entry 1

Cavanagh Bethany J · CIK 0002033155 · SVP, Finance and Treasurer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 51,171

F1 · kind: These shares of common stock were automatically sold in a non-discretionary transaction by the Reporting Person in order to cover tax withholding obligations upon the vesting of certain restricted stock units granted to the Reporting Person under the Beam Therapeutics Inc. 2019 Equity Incentive Plan on each of March 31, 2022, March 31, 2023, March 31, 2024 and March 31, 2025. The sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 9, 2024.

SEC source: 0001193125-26-144086 · ownership.xml · nonDerivative · entry 1

Evans John M. · CIK 0001786304 · Director · CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,047,205

F1 · kind: These shares of common stock were automatically sold in a non-discretionary transaction by the Reporting Person in order to cover tax withholding obligations upon the vesting of certain restricted stock units granted to the Reporting Person under the Beam Therapeutics Inc. ("BEAM") 2019 Equity Incentive Plan on each of March 31, 2022, March 31, 2023, March 31, 2024 and March 31, 2025. The sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 19, 2023.

F2 · balance_after: Includes 616 shares acquired by the Reporting Person under the BEAM Amended and Restated 2019 Employee Stock Purchase Plan on March 31, 2026.

SEC source: 0001193125-26-144080 · ownership.xml · nonDerivative · entry 1

Simon Amy · CIK 0001963879 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 102,735

F1 · kind: These shares of common stock were automatically sold in a non-discretionary transaction by the Reporting Person in order to cover tax withholding obligations upon the vesting of certain restricted stock units granted to the Reporting Person under the Beam Therapeutics Inc. ("BEAM") 2019 Equity Incentive Plan on each of March 31, 2022, March 31, 2023, March 31, 2024 and March 31, 2025. The sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 19, 2023.

F2 · balance_after: Includes 183 and 138 shares acquired by the Reporting Person under the BEAM Amended and Restated 2019 Employee Stock Purchase Plan on September 30, 2025 and March 31, 2026, respectively.

SEC source: 0001193125-26-144067 · ownership.xml · nonDerivative · entry 1

Bellon Christine · CIK 0001963878 · Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 109,711

F1 · kind: These shares of common stock were automatically sold in a non-discretionary transaction by the Reporting Person in order to cover tax withholding obligations upon the vesting of certain restricted stock units granted to the Reporting Person under the Beam Therapeutics Inc. 2019 Equity Incentive Plan on each of March 31, 2022, March 31, 2023, March 31, 2024 and March 31, 2025. The sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 19, 2023.

SEC source: 0001193125-26-144054 · ownership.xml · nonDerivative · entry 1

Ciaramella Giuseppe · CIK 0001786322 · President

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 218,406

F1 · kind: These shares of common stock were automatically sold in a non-discretionary transaction by the Reporting Person in order to cover tax withholding obligations upon the vesting of certain restricted stock units granted to the Reporting Person under the Beam Therapeutics Inc. 2019 Equity Incentive Plan on each of March 31, 2022, March 31, 2023, March 31, 2024 and March 31, 2025. The sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 23, 2023.

SEC source: 0001193125-26-138348 · ownership.xml · derivative · entry 8

Evans John M. · CIK 0001786304 · Director · CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 18,672

Underlying: Common Stock · 25,000 shares

Expires 2028-05-08

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: These shares of common stock were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 16, 2025.

F5 · derivative.exercise_date: On May 8, 2018, the Reporting Person was granted an option to purchase shares of common stock, which vested as to 99,396 shares upon the achievement of a certain development milestone related to base editing applications. On April 3, 2024, the board of directors of BEAM determined that this performance condition was achieved, resulting in the vesting of 99,336 shares.

SEC source: 0001193125-26-138348 · ownership.xml · nonDerivative · entry 5

Evans John M. · CIK 0001786304 · Director · CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,076,667

F4 · shares: Represents restricted stock units ("RSUs") granted to the Reporting Person under the BEAM 2019 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of BEAM's common stock. The RSUs vest in four substantially equal installments on each of the first four anniversaries of the date of grant, subject to the Reporting Person's continued service with BEAM through each vesting date.

SEC source: 0001193125-26-138348 · ownership.xml · nonDerivative · entry 4

Evans John M. · CIK 0001786304 · Director · CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 986,667

F1 · kind: These shares of common stock were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 16, 2025.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $22.34 to $23.21, inclusive. The Reporting Person undertakes to provide to BEAM, any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

SEC source: 0001193125-26-138348 · ownership.xml · nonDerivative · entry 3

Evans John M. · CIK 0001786304 · Director · CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,011,667

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: These shares of common stock were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 16, 2025.

SEC source: 0001193125-26-140553 · ownership.xml · nonDerivative · entry 1

Cavanagh Bethany J · CIK 0002033155 · SVP, Finance and Treasurer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 54,813

F1 · shares: Represents restricted stock units ("RSUs") granted to the Reporting Person under the Beam Therapeutics Inc. ("BEAM") 2019 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of BEAM's common stock. The RSUs vest in four substantially equal installments on each of the first four anniversaries of the date of grant, subject to the Reporting Person's continued service with BEAM through each vesting date.

SEC source: 0001193125-26-140586 · ownership.xml · nonDerivative · entry 1

Bellon Christine · CIK 0001963878 · Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 115,667

F1 · shares: Represents restricted stock units ("RSUs") granted to the Reporting Person under the Beam Therapeutics Inc. ("BEAM") 2019 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of BEAM's common stock. The RSUs vest in four substantially equal installments on each of the first four anniversaries of the date of grant, subject to the Reporting Person's continued service with BEAM through each vesting date.

SEC source: 0001193125-26-140513 · ownership.xml · nonDerivative · entry 1

Emany Sravan Kumar · CIK 0001897662 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 105,456

F1 · shares: Represents restricted stock units ("RSUs") granted to the Reporting Person under the Beam Therapeutics Inc. ("BEAM") 2019 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of BEAM's common stock. The RSUs vest in four substantially equal installments on each of the first four anniversaries of the date of grant, subject to the Reporting Person's continued service with BEAM through each vesting date.

SEC source: 0001193125-26-140515 · ownership.xml · nonDerivative · entry 1

Simon Amy · CIK 0001963879 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 109,114

F1 · shares: Represents restricted stock units ("RSUs") granted to the Reporting Person under the Beam Therapeutics Inc. ("BEAM") 2019 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of BEAM's common stock. The RSUs vest in four substantially equal installments on each of the first four anniversaries of the date of grant, subject to the Reporting Person's continued service with BEAM through each vesting date.

SEC source: 0001193125-26-140508 · ownership.xml · nonDerivative · entry 1

Ciaramella Giuseppe · CIK 0001786322 · President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 230,216

F1 · shares: Represents restricted stock units ("RSUs") granted to the Reporting Person under the Beam Therapeutics Inc. ("BEAM") 2019 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of BEAM's common stock. The RSUs vest in four substantially equal installments on each of the first four anniversaries of the date of grant, subject to the Reporting Person's continued service with BEAM through each vesting date.

SEC source: 0001193125-26-138348 · ownership.xml · derivative · entry 7

Evans John M. · CIK 0001786304 · Director · CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 43,672

Underlying: Common Stock · 25,000 shares

Expires 2028-05-08

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: These shares of common stock were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 16, 2025.

F5 · derivative.exercise_date: On May 8, 2018, the Reporting Person was granted an option to purchase shares of common stock, which vested as to 99,396 shares upon the achievement of a certain development milestone related to base editing applications. On April 3, 2024, the board of directors of BEAM determined that this performance condition was achieved, resulting in the vesting of 99,336 shares.

SEC source: 0001193125-26-138348 · ownership.xml · nonDerivative · entry 2

Evans John M. · CIK 0001786304 · Director · CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 986,667

F1 · kind: These shares of common stock were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 16, 2025.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $22.03 to $22.70, inclusive. The Reporting Person undertakes to provide to Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

SEC source: 0001193125-26-138348 · ownership.xml · nonDerivative · entry 1

Evans John M. · CIK 0001786304 · Director · CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,011,667

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: These shares of common stock were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 16, 2025.

SEC source: 0001193125-26-076544 · ownership.xml · derivative · entry 3

Ciaramella Giuseppe · CIK 0001786322 · President

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 397,313

Underlying: Common Stock · 35,000 shares

Expires 2030-02-05

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: The option vests as to 25% on the first anniversary of the of the vesting commencement date, February 5, 2020, and at a rate of 2.78% each month thereafter until the option is fully vested.

SEC source: 0001193125-26-076544 · ownership.xml · nonDerivative · entry 2

Ciaramella Giuseppe · CIK 0001786322 · President

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 190,216

F1 · kind: The shares of Common Stock were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 30, 2025.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $32.00 to $32.04, inclusive. The Reporting Person undertakes to provide to Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

SEC source: 0001193125-26-076544 · ownership.xml · nonDerivative · entry 1

Ciaramella Giuseppe · CIK 0001786322 · President

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 225,216

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001193125-26-033605 · ownership.xml · derivative · entry 1

Cavanagh Bethany J · CIK 0002033155 · SVP, Finance and Treasurer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 40,000

Underlying: Common Stock · 40,000 shares

Expires 2036-01-31

F1 · derivative.exercise_date: This stock option vests in equal monthly installments each month following the date of grant for the subsequent 48 months, subject to the Reporting Person's continued service with Beam Therapeutics Inc. through each vesting date.

SEC source: 0001193125-26-033606 · ownership.xml · derivative · entry 1

Ciaramella Giuseppe · CIK 0001786322 · President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 80,000

Underlying: Common Stock · 80,000 shares

Expires 2036-01-31

F1 · derivative.exercise_date: This stock option vests in equal monthly installments each month following the date of grant for the subsequent 48 months, subject to the Reporting Person's continued service with BEAM through each vesting date.

SEC source: 0001193125-26-033603 · ownership.xml · derivative · entry 1

Emany Sravan Kumar · CIK 0001897662 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 63,500

Underlying: Common Stock · 63,500 shares

Expires 2036-01-31

F1 · derivative.exercise_date: This stock option vests in equal monthly installments each month following the date of grant for the subsequent 48 months, subject to the Reporting Person's continued service with Beam Therapeutics Inc. through each vesting date.